- Total Q3 revenue increased 11% YoY to $2.80B, led by growth portfolio contributions from acquired Apellis assets.
- GAAP diluted EPS declined to $(0.14) due to transaction charges, while Non-GAAP diluted EPS reached $2.62.
- Legacy MS franchise contracted 13% YoY to $919M, offsetting gains in rare diseases (+27%).
? Neutral AI Sentiment (-1.0 / 10)